Home
About Us
About ReNeuron
Board of Directors
Senior Management
Advisory Board
Working at ReNeuron
Patents
Exosomes
iPSC
Products
Products
Our Products & Technologies
hRPCs for Retinal Disease
CTX cells for Stroke Disability
ReNcell Products
Publications
Clinical Trials
Clinical Trials
Phase 1/2a clinical trial in retinitis pigmentosa
Phase 2b Clinical trial in stroke disability (PISCES III)
Phase 2a clinical trial in stroke disability (PISCES-II)
Phase 1 clinical trial in stroke disability (PISCES)
Observational study in stroke
News
News Centre
News
Events
Media Coverage
Investors
Investor Centre
Corporate Governance
Share Price Information
Major Shareholdings
Advisors
Analyst Research
Financial Reports
General Meetings
Webcasts and Presentations
Financial Calendar
Email alerts
RNS Notifications
Documents and Circulars
AIM Rule 26
Declarations
Contact
Contact Us
Home
About Us
About ReNeuron
Board of Directors
Senior Management
Advisory Board
Working at ReNeuron
Patents
Exosomes
iPSC
Products
Products
Our Products & Technologies
hRPCs for Retinal Disease
CTX cells for Stroke Disability
ReNcell Products
Publications
Clinical Trials
Clinical Trials
Phase 1/2a clinical trial in retinitis pigmentosa
Phase 2b Clinical trial in stroke disability (PISCES III)
Phase 2a clinical trial in stroke disability (PISCES-II)
Phase 1 clinical trial in stroke disability (PISCES)
Observational study in stroke
News
News Centre
News
Events
Media Coverage
Investors
Investor Centre
Corporate Governance
Share Price Information
Major Shareholdings
Advisors
Analyst Research
Financial Reports
General Meetings
Webcasts and Presentations
Financial Calendar
Email alerts
RNS Notifications
Documents and Circulars
AIM Rule 26
Declarations
Contact
Contact Us
Proactive Investors ‘ReNeuron Group’s phase IIb stroke trial kicks off with first patient treated’
Back
Section: News
News Centre
News
News Archive
Events
Media Coverage